CHINA PHARMA HOLDINGS, INC. Asset Impairment Charges
CHINA PHARMA HOLDINGS, INC. (CPHI) reported Asset Impairment Charges of $17.02 million for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AssetImpairmentCharges · last filed 2021-03-26
- CHINA PHARMA HOLDINGS, INC. asset impairment charges for the quarter ending 2017-12-31 was $12.02M, a 381.86% increase year-over-year.
- CHINA PHARMA HOLDINGS, INC. asset impairment charges for the quarter ending 2017-09-30 was $1.18M, a 83.67% increase year-over-year.
- CHINA PHARMA HOLDINGS, INC. asset impairment charges for the quarter ending 2017-06-30 was $977.98K, a 18.90% increase year-over-year.
- CHINA PHARMA HOLDINGS, INC. asset impairment charges for the quarter ending 2016-12-31 was $2.49M.
- CHINA PHARMA HOLDINGS, INC. asset impairment charges for fiscal 2019 was $17.02M, a 162.62% increase from fiscal 2018.
- CHINA PHARMA HOLDINGS, INC. asset impairment charges for fiscal 2018 was $6.48M, a 54.32% decline from fiscal 2017.
- CHINA PHARMA HOLDINGS, INC. asset impairment charges for fiscal 2017 was $14.18M, a 257.99% increase from fiscal 2016.
- CHINA PHARMA HOLDINGS, INC. asset impairment charges for fiscal 2016 was $3.96M.
| Period end | Asset Impairment Charges 3 month | Asset Impairment Charges 6 month | Asset Impairment Charges 9 month | Asset Impairment Charges 12 month |
|---|---|---|---|---|
| 2019-12-31 | $17.02M 10-K · filed 2021-03-26 | |||
| 2018-12-31 | $6.48M 10-K · filed 2020-03-30 | |||
| 2017-12-31 | $12.02M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | $13.21M derived: sum of 2 quarters · filed 2019-03-28 | $14.18M derived: sum of 3 quarters · filed 2019-03-28 | $14.18M 10-K · filed 2019-03-28 |
| 2017-09-30 | $1.18M 10-Q · filed 2018-11-14 | $2.16M derived: sum of 2 quarters · filed 2018-11-14 | $2.16M 10-Q · filed 2018-11-14 | |
| 2017-06-30 | $977.98K 10-Q · filed 2018-08-14 | $977.98K 10-Q · filed 2018-08-14 | ||
| 2016-12-31 | $2.49M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $3.14M derived: sum of 2 quarters · filed 2018-04-02 | $3.96M derived: sum of 3 quarters · filed 2018-04-02 | $3.96M 10-K · filed 2018-04-02 |
| 2016-09-30 | $644.70K 10-Q · filed 2017-11-14 | $1.47M derived: sum of 2 quarters · filed 2017-11-14 | $1.47M 10-Q · filed 2017-11-14 | |
| 2016-06-30 | $822.54K 10-Q · filed 2017-08-14 | $822.54K 10-Q · filed 2017-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |